133 related articles for article (PubMed ID: 38880225)
1. HIF-2α Inhibition Disrupts Leukemia Stem Cell Metabolism and Impairs Vascular Microenvironment to Enhance Chronic Myeloid Leukemia Treatment.
Wang J; Ma W; Huang J; Qiu G; Zhang T; Wei Q; He C; Zhou D; Zhao M; Chen C; Xu X
Cancer Lett; 2024 Jun; ():217060. PubMed ID: 38880225
[TBL] [Abstract][Full Text] [Related]
2. Overcoming BCR::ABL1 dependent and independent survival mechanisms in chronic myeloid leukaemia using a multi-kinase targeting approach.
Busch C; Mulholland T; Zagnoni M; Dalby M; Berry C; Wheadon H
Cell Commun Signal; 2023 Nov; 21(1):342. PubMed ID: 38031192
[TBL] [Abstract][Full Text] [Related]
3. Mesenchymal Niche-Specific Expression of Cxcl12 Controls Quiescence of Treatment-Resistant Leukemia Stem Cells.
Agarwal P; Isringhausen S; Li H; Paterson AJ; He J; Gomariz Á; Nagasawa T; Nombela-Arrieta C; Bhatia R
Cell Stem Cell; 2019 May; 24(5):769-784.e6. PubMed ID: 30905620
[TBL] [Abstract][Full Text] [Related]
4. Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia.
Zhang B; Nguyen LXT; Li L; Zhao D; Kumar B; Wu H; Lin A; Pellicano F; Hopcroft L; Su YL; Copland M; Holyoake TL; Kuo CJ; Bhatia R; Snyder DS; Ali H; Stein AS; Brewer C; Wang H; McDonald T; Swiderski P; Troadec E; Chen CC; Dorrance A; Pullarkat V; Yuan YC; Perrotti D; Carlesso N; Forman SJ; Kortylewski M; Kuo YH; Marcucci G
Nat Med; 2018 May; 24(4):450-462. PubMed ID: 29505034
[TBL] [Abstract][Full Text] [Related]
5. Hif-1α and Hif-2α synergize to suppress AML development but are dispensable for disease maintenance.
Vukovic M; Guitart AV; Sepulveda C; Villacreces A; O'Duibhir E; Panagopoulou TI; Ivens A; Menendez-Gonzalez J; Iglesias JM; Allen L; Glykofrydis F; Subramani C; Armesilla-Diaz A; Post AE; Schaak K; Gezer D; So CW; Holyoake TL; Wood A; O'Carroll D; Ratcliffe PJ; Kranc KR
J Exp Med; 2015 Dec; 212(13):2223-34. PubMed ID: 26642852
[TBL] [Abstract][Full Text] [Related]
6. Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-β-catenin signaling.
Zhang B; Li M; McDonald T; Holyoake TL; Moon RT; Campana D; Shultz L; Bhatia R
Blood; 2013 Mar; 121(10):1824-38. PubMed ID: 23299311
[TBL] [Abstract][Full Text] [Related]
7. Leukemic stem cells shall be searched in the bone marrow before "tyrosine kinase inhibitor-discontinuation" in chronic myeloid leukemia.
Ilhan O; Narli Ozdemir Z; Dalva K; Arslan A; Okay Ozgeyik M; Ipek S; Saydam G; Haznedaroglu IC
Int J Lab Hematol; 2021 Oct; 43(5):1110-1116. PubMed ID: 33834631
[TBL] [Abstract][Full Text] [Related]
8. The role of Fas-associated phosphatase 1 in leukemia stem cell persistence during tyrosine kinase inhibitor treatment of chronic myeloid leukemia.
Huang W; Luan CH; Hjort EE; Bei L; Mishra R; Sakamoto KM; Platanias LC; Eklund EA
Leukemia; 2016 Jul; 30(7):1502-9. PubMed ID: 26984787
[TBL] [Abstract][Full Text] [Related]
9. Infliximab therapy together with tyrosine kinase inhibition targets leukemic stem cells in chronic myeloid leukemia.
Herrmann O; Kuepper MK; Bütow M; Costa IG; Appelmann I; Beier F; Luedde T; Braunschweig T; Koschmieder S; Brümmendorf TH; Schemionek M
BMC Cancer; 2019 Jul; 19(1):658. PubMed ID: 31272418
[TBL] [Abstract][Full Text] [Related]
10. YBX1 regulates the survival of chronic myeloid leukemia stem cells by modulating m
Chai J; Wang Q; Qiu Q; Han G; Chen Y; Li W; Zhang H
Cell Oncol (Dordr); 2023 Apr; 46(2):451-464. PubMed ID: 36512307
[TBL] [Abstract][Full Text] [Related]
11. Chronic myeloid leukemia stem cells: targeting therapeutic implications.
Mojtahedi H; Yazdanpanah N; Rezaei N
Stem Cell Res Ther; 2021 Dec; 12(1):603. PubMed ID: 34922630
[TBL] [Abstract][Full Text] [Related]
12. Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells.
Salati S; Salvestrini V; Carretta C; Genovese E; Rontauroli S; Zini R; Rossi C; Ruberti S; Bianchi E; Barbieri G; Curti A; Castagnetti F; Gugliotta G; Rosti G; Bergamaschi M; Tafuri A; Tagliafico E; Lemoli R; Manfredini R
Oncotarget; 2017 Jul; 8(30):49451-49469. PubMed ID: 28533480
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic Reprogramming Sensitizes CML Stem Cells to Combined EZH2 and Tyrosine Kinase Inhibition.
Scott MT; Korfi K; Saffrey P; Hopcroft LE; Kinstrie R; Pellicano F; Guenther C; Gallipoli P; Cruz M; Dunn K; Jorgensen HG; Cassels JE; Hamilton A; Crossan A; Sinclair A; Holyoake TL; Vetrie D
Cancer Discov; 2016 Nov; 6(11):1248-1257. PubMed ID: 27630125
[TBL] [Abstract][Full Text] [Related]
14. Targeting chronic myeloid leukemia stem cells with the hypoxia-inducible factor inhibitor acriflavine.
Cheloni G; Tanturli M; Tusa I; Ho DeSouza N; Shan Y; Gozzini A; Mazurier F; Rovida E; Li S; Dello Sbarba P
Blood; 2017 Aug; 130(5):655-665. PubMed ID: 28576876
[TBL] [Abstract][Full Text] [Related]
15. TNF-α-induced alterations in stromal progenitors enhance leukemic stem cell growth via CXCR2 signaling.
Agarwal P; Li H; Choi K; Hueneman K; He J; Welner RS; Starczynowski DT; Bhatia R
Cell Rep; 2021 Jul; 36(2):109386. PubMed ID: 34260914
[TBL] [Abstract][Full Text] [Related]
16. Metabolic adaptation to tyrosine kinase inhibition in leukemia stem cells.
Qiu S; Sheth V; Yan C; Liu J; Chacko BK; Li H; Crossman DK; Fortmann SD; Aryal S; Rennhack A; Grant MB; Welner RS; Paterson AJ; Wende AR; Darley-Usmar VM; Lu R; Locasale JW; Bhatia R
Blood; 2023 Aug; 142(6):574-588. PubMed ID: 37192295
[TBL] [Abstract][Full Text] [Related]
17. Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL/MYC-signaling: effect on imatinib resistance and stem cells.
Lernoux M; Schnekenburger M; Losson H; Vermeulen K; Hahn H; Gérard D; Lee JY; Mazumder A; Ahamed M; Christov C; Kim DW; Dicato M; Bormans G; Han BW; Diederich M
Clin Epigenetics; 2020 May; 12(1):69. PubMed ID: 32430012
[TBL] [Abstract][Full Text] [Related]
18. Leukemia Stem Cells as a Potential Target to Achieve Therapy-Free Remission in Chronic Myeloid Leukemia.
Ito K; Ito K
Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830976
[TBL] [Abstract][Full Text] [Related]
19. Hypoxia-inducible factor 1α inhibitor induces cell death via suppression of BCR-ABL1 and Met expression in BCR-ABL1 tyrosine kinase inhibitor sensitive and resistant chronic myeloid leukemia cells.
Tsubaki M; Takeda T; Matsuda T; Kimura A; Tanaka R; Nagayoshi S; Hoshida T; Tanabe K; Nishida S
BMB Rep; 2023 Feb; 56(2):78-83. PubMed ID: 36195570
[TBL] [Abstract][Full Text] [Related]
20. Targeting BMP signaling in the bone marrow microenvironment of myeloid leukemia.
Lefort S; Maguer-Satta V
Biochem Soc Trans; 2020 Apr; 48(2):411-418. PubMed ID: 32167132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]